Bladder, Kidney and Genitals
-
A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder
In this plain language summary published in Journal of Comparative Effectiveness Research, learn about a study that looked at how likely it is that individual people with overactive bladder will achieve a certain level of improvement in their symptoms when taking fesoterodine.
-
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
Summary and patient perspectives of the ARASENS trial looking at treatment with darolutamide compared to placebo in combination with docetaxel and androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer.
-
Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer
This is plain language summary provides an overview of the HERO study looking at how well relugolix works, compared with leuprolide, in men with advanced prostate cancer.
-
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial
The latest plain language summary of publication (PLSP) published in Future Oncology provides a summary of the ARAMIS trial.